Table 3.
Prediction of stability at 6 months from administration of anti-fibrotic drugs in univariate analysis
| Variable | OR (95% CI) | P-value |
|---|---|---|
| Sex, Male | 0.64 (0.15–2.83) | 0.55 |
| Age | 1.05 (0.96–1.14) | 0.24 |
| Smokers | 1.27 (0.33–4.96) | 0.72 |
| Pack-years smoking | 1.01 (0.99–1.03) | 0.59 |
| BMI | 0.89 (0.74–1.08) | 0.22 |
| % FVC (%) | 1.01 (0.98–1.04) | 0.61 |
| % DLco (%) | 1.00 (0.95–1.04) | 0.83 |
| PaO2 at rest (Torr) | 1.01 (0.94–1.09) | 0.71 |
| Minimum SpO2 during 6MWT (%) | 1.06 (0.93–1.21) | 0.37 |
| 6MWT Distance (m) | 1.00 (0.99–1.01) | 0.80 |
| SP-A (ng/mL) | 0.99 (0.98–1.01) | 0.30 |
| SP-D (ng/mL) | 1.00 (1.00–1.00) | 0.64 |
| KL-6 (U/mL) | 1.00 (1.00–1.00) | 0.65 |
| Pirfenidone | 2.01 (0.62–6.99) | 0.23 |
| Treatment history of anti-fibrotic drugs (n) | 0.69 (0.14–3.53) | 0.66 |
| Change in SP-A in 3 months (%) | 0.89 (0.82–0.96) | < 0.01 |
| Change in SP-D in 3 months (%) | 0.98 (0.96–1.00) | 0.12 |
| Change in KL-6 in 3 months (%) | 0.96 (0.92–0.99) | < 0.01 |
| Change in SP-A in 6 months (%) | 0.89 (0.84–0.95) | < 0.01 |
| Change in SP-D in 6 months (%) | 0.95 (0.92–0.99) | < 0.01 |
| Change in KL-6 in 6 months (%) | 0.93 (0.89–0.97) | < 0.01 |
OR odd’s ratio; BMI body mass index; FVC forced vital capacity; DLco diffusing capacity of the lung for carbon monoxide; PaO2 partial pressure of arterial oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6 min-walk test; SP surfactant protein; KL-6 Krebs von den Lungen-6